This vaccine has demonstrated efficacy in preclinical models of colon cancer via the induction of humoral anti-5T4 responses. Early indications in mCRC demonstrated an excellent safety profile, with the induction of anti-5T4 responses correlating with disease control, thus warranting further studies in randomized clinical trials. Here, TPBG is linked to malignant colon neoplasm.